Selected References:
- DeSisto CL, et al. 2021. Risk of stillbirth among women with and without COVID-19 at delivery hospitalization – United States, March 2020 – September 2021. MMWR Morb Mortal Wkly Rep. 70(47):1640-1645.
- Hashemian SMR, et al. 2022. RdRp inhibitors and COVID-19: Is molnupiravir a good option? Biomed Pharmacother. 146:112517.
- Li G. et al. 2023. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 22(6):449-475.
- Kasehagen L, et al. 2021. COVID-19 – associated deaths after SARS-CoV-2 infection during pregnancy – Mississippi, March 1, 2020 – October 6, 2021. MMWR Morb Mortal Wkly Rep. 70(47):1646-1648.
- Merck Sharp & Dohme LLC. 2024. Lagevrio product labeling. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1b0da643-ab23-4a0b-a9ec-a434522446d0&type=display. Accessed 10 August 2026.
- Pagliano P et al. 2022. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19). Expert Opin Drug Discov. 17(12):1299-1311.
- Regan AK, et al. 2022. SARS-CoV-2 infection during pregnancy and associated perinatal health outcomes: a national US cohort study. J Infect Dis. 225(5):759-767.
- U.S. Food & Drug Administration, Antimicrobial Drugs Advisory Committee. November 30, 2021. Molnupiravir. Available at: https://www.fda.gov/media/165856/download. Accessed 10 August 2026.
- U.S. Food & Drug Administration. 2021 (Revised October 2023). Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir. Available at https://www.fda.gov/media/155054/download. Accessed 10 August 2026.
- Wan EYF, et al. 2025. Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and molnupiravir versus monotherapy with molnupiravir or nirmatrelvir-ritonavir in hospitalized COVID-19 patients: A target trial emulation study. Int J Infect Dis161:108097.
